Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.AP Pharma has completed patient enrollment in its pivotal Phase III study in chemotherapy-induced nausea and vomiting comparing the efficacy of APF530 with Aloxi for the prevention of acute and delayed onset chemotherapy-induced nausea and vomiting in both moderate and highly emetogenic chemotherapy treatments.
Subscribe to our email newsletter
The trial is being conducted in the US, India and Poland. Data collection will be finalized following completion of treatment of the last patients, expected near the end of July 2008.
The results of the trial will be announced following the unblinding of data, which is anticipated to occur late in the third quarter of 2008.